Rapport Therapeutics, Inc.（股票代码：RAPP）今日盘前股价大涨171.59%，引发市场广泛关注。这一显著涨幅主要源于该公司宣布其实验性癫痫药物RAP-219在中期临床试验中取得积极结果。
根据公司公布的数据，RAP-219在针对难以治疗的局灶性癫痫发作成人患者的2a期临床试验中表现出色。经过8周的治疗，患者的癫痫发作次数中位数下降了77.8%，更值得注意的是，24%的患者在试验期间完全摆脱了癫痫发作。该药物还表现出良好的耐受性，不良反应大多轻微。这些结果显示了RAP-219在治疗难治性癫痫方面的巨大潜力。
Rapport Therapeutics表示，计划在2025年第四季度与美国食品药品监督管理局（FDA）举行2期试验结束会议，并有意在2026年第三季度启动两项后期研究。市场对这一进展反应积极，推动公司股价在盘前交易中大幅攀升，从前一交易日的收盘价显著上涨。考虑到该公司此前年内股价累计下跌19.5%，这次利好消息无疑为投资者注入了新的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.